BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF(V600E)) metastatic colorectal cancer (mCRC) Meeting Abstract
| Authors: | Kopetz, S.; Yoshino, T.; Kim, T. W.; Desai, J.; Yaeger, R.; Van Cutsem, E.; Ciardiello, F.; Wasan, H. S.; Maughan, T.; Zhang, Y.; Usari, T.; Chung, C. H.; Zhang, X.; Tabernero, J. |
| Abstract Title: | BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF(V600E)) metastatic colorectal cancer (mCRC) |
| Meeting Title: | 2022 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2022 Jan 20-22 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-01 |
| Language: | English |
| ACCESSION: | WOS:000770995900130 |
| DOI: | 10.1200/JCO.2022.40.4_suppl.134 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 134 -- Meeting was conducted online as well as in person -- Source: Wos |
